Palvella Therapeutics Inc expected to post a loss of 74 cents a share - Earnings Preview

Palvella Therapeutics

12/08/2025 13:57

Palvella Therapeutics Inc PVLA.OQ PVLA.O is expected to  report resultson August 14 for the period ending June 30 2025

​LSEG's mean analyst estimate for Palvella Therapeutics Inc is for a loss of 74 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Palvella Therapeutics Inc is $50.00, about 16.6% above its last closing price of $41.71

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-1.30
-1.21
-0.74
Beat
38.9
Dec. 31 2025
-0.66
-0.64
-2.72
Missed
-321.7
​
​​
-3.70
​
Sep. 30 2023
-8.80
-8.80
3.20
Beat
136.4
Jun. 30 2023
-12.80
-12.80
4.00
Beat
131.3

This summary was machine generated August 12 at 12:57 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)